Quick Takeaways
- GREAT POINT PARTNERS LLC filed SCHEDULE 13G/A for Vistagen Therapeutics, Inc. Common Stock, $0.001 par value per share (VTGN).
- Disclosed ownership: 6.6%.
- Date of event: 30 Jun 2025.
GREAT POINT PARTNERS LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Vistagen Therapeutics, Inc. Common Stock, $0.001 par value per share (VTGN)
- Filing Manager
- GREAT POINT PARTNERS LLC
- Reporting Manager
- Great Point Partners, LLC
- Symbol
- VTGN
- Shares outstanding
- 31,196,267 shares
- Disclosed Ownership
- 2,055,834 shares
- Ownership
- 6.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 17:13:28 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 15 May 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GREAT POINT PARTNERS LLC disclosed 6.6% ownership in Vistagen Therapeutics, Inc. Common Stock, $0.001 par value per share (VTGN) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 15 May 2025.
- Current filing was accepted on 14 Aug 2025, 17:13.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Great Point Partners, LLC | 6.6% | 2,055,834 | 0 | 2,055,834 | /s/ Dr. Jeffrey R. Jay, M.D | Dr. Jeffrey R. Jay, M.D - Senior Managing Member | |
| Dr. Jeffrey R. Jay, M.D. | 6.6% | 2,055,834 | 0 | 2,055,834 | /s/ Dr. Jeffrey R. Jay, M.D | Dr. Jeffrey R. Jay, M.D | |
| Ms. Lillian Nordahl | 6.6% | 2,055,834 | 0 | 2,055,834 | /s/ Ms. Lillian Nordahl | Ms. Lillian Nordahl |